intravenous cangrelor (Kengrexal°) and coronary angioplasty: No advantage over first-line clopidogrel.
In three comparative trials in a total of about 25,000 patients requiring coronary angioplasty, IV cangrelor was not more effective in reducing mortality than oral clopidogrel, and it only improved cardiovascular morbidity in a biased trial. Cangrelor can provoke bleeding, kidney failure and dyspnea.